iRhythm Technologies Management

Management Kriterienprüfungen 2/4

iRhythm Technologies' CEO ist Quentin Blackford , ernannt in Oct 2021, hat eine Amtszeit von 2.67 Jahren. Die jährliche Gesamtvergütung beträgt $16.60M , bestehend aus 4.1% Gehalt und 95.9% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.23% der Aktien des Unternehmens, im Wert von $6.92M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 2 Jahre bzw. 6.9 Jahre.

Wichtige Informationen

Quentin Blackford

Geschäftsführender

US$16.6m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	4.1%
Amtszeit als Geschäftsführer	2.7yrs
Eigentum des Geschäftsführers	0.2%
Durchschnittliche Amtszeit des Managements	2yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	6.9yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Quentin Blackford im Vergleich zu den Einnahmen von iRhythm Technologies verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 31 2024	n/a	n/a	-US$130m
Dec 31 2023	US$17m	US$677k	-US$123m
Sep 30 2023	n/a	n/a	-US$105m
Jun 30 2023	n/a	n/a	-US$99m
Mar 31 2023	n/a	n/a	-US$105m
Dec 31 2022	US$8m	US$650k	-US$116m
Sep 30 2022	n/a	n/a	-US$128m
Jun 30 2022	n/a	n/a	-US$131m
Mar 31 2022	n/a	n/a	-US$124m
Dec 31 2021	US$10m	US$163k	-US$101m

Vergütung im Vergleich zum Markt: QuentinDie Gesamtvergütung ($USD16.60M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt UK ($USD2.46M).

Entschädigung vs. Einkommen: QuentinDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

Geschäftsführer

Quentin Blackford (45 yo)

2.7yrs

Amtszeit

US$16,595,149

Vergütung

Mr. Quentin S. Blackford serves as an Independent Director of Paragon 28, Inc. since August 1, 2022. He serves as President and Chief Executive Officer since October 04, 2021 and serves as Director at iRhy...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Quentin Blackford	President	2.7yrs	US$16.60m	0.23% $ 7.4m
Brice Bobzien	Chief Financial Officer	1.8yrs	US$5.28m	0.0085% $ 272.6k
Minang Turakhia	Chief Medical & Scientific Officer and Executive VP of Product Innovation	2.2yrs	US$5.32m	0.011% $ 357.0k
Patrick Murphy	Chief Business & Legal Officer	2.5yrs	US$5.33m	0.031% $ 982.5k
Chad Patterson	Chief Commercial Officer	1.9yrs	US$5.77m	0.017% $ 548.3k
Mervin Smith	Executive Vice President of Business Operations	less than a year	keine Daten	keine Daten
Marc Rosenbaum	Senior VP of Finance & Chief Accounting Officer	less than a year	keine Daten	0.0029% $ 93.4k
Daniel Wilson	Executive VP of Corporate Development & Investor Relations	5yrs	US$3.54m	0.098% $ 3.1m
Douglas Devine	Executive Advisor	1.3yrs	US$2.72m	0.055% $ 1.8m
Sumi Shrishrimal	Executive VP & Chief Risk Officer	2.1yrs	keine Daten	0.075% $ 2.4m
Stephanie Zhadkevich	Director of Investor Relations	no data	keine Daten	keine Daten

2.0yrs

Durchschnittliche Betriebszugehörigkeit

45yo

Durchschnittliches Alter

Erfahrenes Management: 0A7LDas Führungsteam des Unternehmens gilt als erfahren (2 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Quentin Blackford	President	2.4yrs	US$16.60m	0.23% $ 7.4m
Ralph Snyderman	Independent Director	6.9yrs	US$233.12k	0.032% $ 1.0m
Michael Mirro	Medical Director & Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Bruce Bodaken	Independent Director	6.9yrs	US$240.25k	0.030% $ 970.9k
Abhijit Talwalkar	Independent Chairman	8.1yrs	US$286.74k	0.034% $ 1.1m
R. Mead	Medical Director & Member of Scientific Advisory Board	no data	keine Daten	keine Daten
James Quinn	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Cathleen Noel Merz	Independent Director	6.2yrs	US$230.62k	0.019% $ 593.8k
Mark Rubash	Independent Director	8.3yrs	US$248.12k	0.034% $ 1.1m
Mehdi Razavi	Medical Director & Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Karen Ling	Independent Director	2.6yrs	US$239.97k	0.020% $ 655.2k
Jay Alexander	Medical Director & Member of Scientific Advisory Board	no data	keine Daten	keine Daten

6.9yrs

Durchschnittliche Betriebszugehörigkeit

67yo

Durchschnittliches Alter

Erfahrener Vorstand: 0A7LDie Vorstandsmitglieder gelten als erfahren (6.9 Jahre durchschnittliche Amtszeit).

iRhythm Technologies Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

iRhythm Technologies, Inc., Annual General Meeting, May 29, 2024

President recently sold US$3.0m worth of stock

Insider recently sold US$746k worth of stock

iRhythm Technologies, Inc. Announces Director Appointments

Executive VP & Chief Risk Officer recently sold US$124k worth of stock

COO & Secretary recently sold US$415k worth of stock

Recent updates

iRhythm Technologies, Inc. Achieves Significant Operational Milestone with Launch of Initial Phase of Manufacturing Automation

First quarter 2024 earnings released: US$1.47 loss per share (vs US$1.29 loss in 1Q 2023)

iRhythm Technologies, Inc. Revises Earnings Guidance for the Year 2024

iRhythm Technologies, Inc. to Report Q1, 2024 Results on May 02, 2024

New minor risk - Profitability

iRhythm Technologies, Inc., Annual General Meeting, May 29, 2024

New minor risk - Shareholder dilution

President recently sold US$3.0m worth of stock

Forecast to breakeven in 2026

New minor risk - Shareholder dilution

iRhythm Technologies, Inc. Provides Earnings Guidance for the Year 2024

iRhythm Technologies, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Bernstein Litowitz Berger & Grossmann LLP Files Securities Class Action Lawsuit Against iRhythm Technologies, Inc

iRhythm Technologies, Inc. Revises Revenue Guidance for the Year 2024

iRhythm , Inc. Announces Results from the Cardiac Ambulatory Monitor EvaLuation of Outcomes and Time to Events

Insider recently sold US$746k worth of stock

iRhythm Technologies, Inc. Provides Revenue Guidance for the Full Year 2023

Third quarter 2023 earnings released: US$0.89 loss per share (vs US$0.71 loss in 3Q 2022)

iRhythm Technologies, Inc. to Report Q3, 2023 Results on Nov 02, 2023

iRhythm Launches Next Generation Zio Monitor and Enhanced Zio Service: Its Smallest, Lightest and Thinnest Cardiac Monitor

iRhythm Technologies, Inc. Provides Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings released: US$0.61 loss per share (vs US$0.80 loss in 2Q 2022)

Now 20% undervalued

iRhythm Technologies, Inc. to Report Q2, 2023 Results on Aug 03, 2023

iRhythm Technologies, Inc. Announces Director Appointments

Executive VP & Chief Risk Officer recently sold US$124k worth of stock

iRhythm Technologies, Inc. Provides Earnings Guidance for the Year 2023

First quarter 2023 earnings released: US$1.29 loss per share (vs US$1.71 loss in 1Q 2022)

Now 20% undervalued

COO & Secretary recently sold US$415k worth of stock

Now 21% undervalued

Full year 2022 earnings released: US$3.88 loss per share (vs US$3.46 loss in FY 2021)

iRhythm Technologies, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Chief Legal Counsel recently sold US$182k worth of stock

iRhythm Technologies, Inc. Revises Earnings Guidance for the Year 2022

iRhythm Technologies, Inc. to Report Q3, 2022 Results on Nov 01, 2022

iRhythm Technologies, Inc. Reiterates Revenue Guidance for the Year 2022

iRhythm Technologies, Inc. Provides Revenue Guidance for the Full Year of 2022

Second quarter 2022 earnings released: US$0.80 loss per share (vs US$0.59 loss in 2Q 2021)

iRhythm Technologies, Inc. Appoints Brice Bobzien as Chief Financial Officer, Effective August 8, 2022

iRhythm Gains FDA Clearance for its Clinically Integrated ZEUS System

iRhythm Technologies, Inc. Announces Management Changes

Executive Vice President of Strategy recently sold US$156k worth of stock

Independent Director recently sold US$56k worth of stock

First quarter 2022 earnings released: US$1.71 loss per share (vs US$0.95 loss in 1Q 2021)

iRhythm Technologies, Inc. Provides Earnings Guidance for the Fiscal Year 2022

iRhythm Technologies, Inc. to Report Q1, 2022 Results on May 05, 2022

iRhythm Technologies, Inc., Annual General Meeting, May 26, 2022

iRhythm Technologies, Inc. Announces the Results of Three Clinical Research Studies Presented At the American College of Cardiology’s 71 Annual Scientific Session & Expo

Consultant & Director recently sold US$904k worth of stock

iRhythm Technologies, Inc. Announces the Results of the KP-Rhythm2 Study

iRhythm Technologies, Inc. Provides Revenue Guidance for the Full Year 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

COO, CFO & Secretary recently sold US$557k worth of stock

iRhythm Technologies, Inc. to Report Q4, 2021 Results on Feb 23, 2022

Insufficient new directors

Third quarter 2021 earnings released: US$0.81 loss per share (vs US$0.17 loss in 3Q 2020)

Insufficient new directors

Second quarter 2021 earnings released: US$0.59 loss per share (vs US$0.75 loss in 2Q 2020)

iRhythm Technologies, Inc. Provides Revenue Guidance for the Full Year of 2021

iRhythm Technologies, Inc.(NasdaqGS:IRTC) dropped from Russell 2000 Growth-Defensive Index

iRhythm Technologies Continues to Fuel Innovation in Cardiac Monitoring and Unveils Two FDA Clearances for Superior Patient Care

iRhythm Technologies, Inc. Provides Earnings Guidance for the First Quarter of 2021

First quarter 2021 earnings released: US$0.95 loss per share (vs US$0.34 loss in 1Q 2020)

Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against iRhythm Technologies, Inc

Full year 2020 earnings released: US$1.58 loss per share (vs US$2.16 loss in FY 2019)

Revenue beats expectations

Study Published in Jama Cardiology Finds Zio by iRhythm Proactively Identifies Atrial Fibrillation, Increases Detection Tenfold

Analyse der Geschäftsführervergütung